Viral vector constructs for delivering nucleic acids encoding cytokines and their use for treating cancer
Patent Information
- Application Number
- JP2023520073
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-30
- Filing Date
- 2021-10-13
- Publication Date
- 2024-11-01
Smart Images

Figure 00000172_0000 
Figure 00000172_0001 
Figure 00000172_0002
Abstract
Claims
1. (a) a first composition comprising an adeno-associated virus (AAV) vector comprising a polynucleotide comprising (i) a promoter; (ii) a first nucleic acid encoding a first interleukin-12 (IL-12) subunit, or a functional fragment thereof; (iii) a translational modification sequence; and (iv) a second nucleic acid encoding a second IL-12 subunit, or a functional fragment thereof; and (b) a second composition comprising a checkpoint inhibitor. A pharmaceutical comprising a combination of The first composition is administered before, simultaneously with, or after administration of the second composition. Medicine.
2. (a) a first composition comprising an adeno-associated virus (AAV) vector comprising a polynucleotide comprising: (i) a promoter; (ii) a first nucleic acid encoding a first interleukin-12 (IL-12) subunit or a functional fragment thereof; (iii) a translation modification sequence; and (iv) a second nucleic acid encoding a second IL-12 subunit or a functional fragment thereof. A pharmaceutical comprising the medicament is used in combination with (b) a second composition comprising a checkpoint inhibitor; The first composition is administered before, simultaneously with, or after administration of the second composition. Medicine.
3. The pharmaceutical composition of claim 1 or 2, wherein the AAV vector is an AAV serotype 2 (AAV2) vector.
4. The pharmaceutical according to any one of claims 1 to 3, wherein the translation modification sequence comprises a furin cleavage sequence, a 2A self-processing peptide sequence, an internal ribosome entry site (IRES) sequence, or any combination thereof.
5. The pharmaceutical of claim 4, wherein the translational modification sequence comprises a furin cleavage sequence and a 2A self-processing peptide sequence (F2A).
6. The pharmaceutical agent according to any one of claims 1 to 5, wherein the promoter comprises a CBA promoter, a CMV promoter, an EF-1a (elongation factor 1a) promoter, an RSV (Rous sarcoma virus) promoter, a ubiquitin (UbC) promoter, a CAG promoter, or any combination thereof.
7. The pharmaceutical according to any one of claims 1 to 6, wherein the polynucleotide further comprises a poly(A) (pA) sequence.
8. The pharmaceutical of any one of claims 1 to 7, wherein the polynucleotide further comprises two inverted terminal repeat (ITR) sequences.
9. 9. The pharmaceutical agent of any one of claims 1 to 8, wherein the checkpoint inhibitor comprises an inhibitor of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin mucin-containing protein 3 (TIM-3), B- and T-lymphocyte attenuator (BTLA), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T-cell activation (VISTA), adenosine A2a receptor (A2aR), killer cell immunoglobulin-like receptor (KIR), indoleamine 2,3-dioxygenase (IDO), CD20, CD39, CD73, inducible T-cell costimulatory molecule (ICOS), B7-H3, or any combination thereof.
10. The pharmaceutical agent of any one of claims 1 to 9, wherein the checkpoint inhibitor comprises a programmed cell death protein 1 (PD-1) inhibitor.
11. The pharmaceutical composition according to claim 10, wherein the PD-1 inhibitor is an anti-PD-1 antibody.
12. The pharmaceutical agent of any one of claims 1 to 11, wherein the first IL-12 subunit comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:80, and the second IL-12 subunit comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:
81.
13. The pharmaceutical agent of any one of claims 1 to 12, wherein the first nucleic acid comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:77, and the second nucleic acid comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:
92.
14. The pharmaceutical agent of any one of claims 1 to 13, wherein the polynucleotide comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:
82.
15. The pharmaceutical composition of any one of claims 1 to 14, wherein the first composition is suitable for intratumoral delivery and the second composition is suitable for intravenous delivery.
16. A medicament according to any one of claims 1 to 15 for use in a method for treating a subject suffering from a tumor.
17. The pharmaceutical described in claim 16, wherein the method includes a step of administering the first composition into a tumor.
18. The pharmaceutical composition of claim 17, wherein the method comprises administering the first composition to multiple sites of a tumor.
19. The pharmaceutical agent of any one of claims 16 to 18, wherein the tumor is derived from a cancer selected from the group consisting of skin cancer, breast cancer, brain cancer, bone cancer, head and neck cancer, salivary gland cancer, gynecological cancer, urinary tract cancer, gastrointestinal cancer, eye cancer, breast cancer, blood cancer, endocrine system cancer, soft tissue sarcoma, central nervous system neoplasm, and any combination thereof.
20. The pharmaceutical agent according to any one of claims 16 to 19, wherein the tumor is derived from a cancer selected from the group consisting of hepatocellular carcinoma, colon cancer, and melanoma.
21. A pharmaceutical for use in a method for expressing IL-12, or a functional fragment thereof, in a subject in need thereof, comprising: The medicine, A first composition comprising an adeno-associated virus (AAV) vector comprising a polynucleotide comprising (i) a promoter, (ii) a first nucleic acid encoding a first interleukin-12 (IL-12) subunit or a functional fragment thereof, (iii) a translational modification sequence, and (iv) a second nucleic acid encoding a second IL-12 subunit or a functional fragment thereof. Including, Medicine.
22. A pharmaceutical for use in a method for delivering IL-12, or a functional fragment thereof, to a tumor in a subject, comprising: The medicine, A first composition comprising an adeno-associated virus (AAV) vector comprising a polynucleotide comprising (i) a promoter, (ii) a first nucleic acid encoding a first interleukin-12 (IL-12) subunit or a functional fragment thereof, (iii) a translational modification sequence, and (iv) a second nucleic acid encoding a second IL-12 subunit or a functional fragment thereof. Including, the method comprising administering the first composition by direct injection into the tumor; Medicine.
23. The AAV vector, wherein the AAV vector is an AAV serotype 2 (AAV2) vector. The translational modification sequence comprises a furin cleavage sequence, a 2A self-processing peptide sequence, an internal ribosome entry site (IRES) sequence, or any combination thereof; The translational modification sequence comprises a furin cleavage sequence and a 2A self-processing peptide sequence (F2A); The promoter comprises a CBA promoter, a CMV promoter, an EF-1a (elongation factor 1a) promoter, an RSV (Rous sarcoma virus) promoter, a ubiquitin (UbC) promoter, a CAG promoter, or any combination thereof; the polynucleotide further comprises a poly(A) (pA) sequence; the polynucleotide further comprises two inverted terminal repeat (ITR) sequences; the first IL-12 subunit comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:80, and the second IL-12 subunit comprises an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:81; the first nucleic acid comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:77, and the second nucleic acid comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:92; and / or the polynucleotide comprises a nucleic acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:82; 23. The pharmaceutical composition according to claim 21 or 22.
24. A medicament according to any one of claims 1 to 15 for use in a method for treating or reducing symptoms in a subject suffering from a tumor, comprising The method comprises administering the first composition intratumorally and administering the second composition intravenously. Medicine.
25. A medicament according to any one of claims 1 to 15 for use in a method for reducing the size of a tumor in a subject in need thereof, comprising The method comprises administering the first composition intratumorally and administering the second composition intravenously. Medicine.
26. The pharmaceutical agent according to any one of claims 22 to 25, wherein the tumor is derived from a cancer selected from the group consisting of hepatocellular carcinoma, colon cancer, melanoma, and any combination thereof.
27. The pharmaceutical agent of any one of claims 21 to 26, wherein the subject is suffering from a cancer selected from the group consisting of hepatocellular carcinoma, colon cancer, melanoma, and any combination thereof.
28. The pharmaceutical agent of any one of claims 16 to 25, wherein the tumor is derived from a cancer selected from the group consisting of skin cancer, breast cancer, brain cancer, bone cancer, head and neck cancer, salivary gland cancer, gynecological cancer, urinary tract cancer, gastrointestinal cancer, eye cancer, breast cancer, blood cancer, lymphoma, endocrine system cancer, soft tissue sarcoma, central nervous system neoplasm, and any combination thereof.
29. The subject is a patient with metastatic melanoma, cutaneous malignant melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, invasive breast cancer, triple-negative breast cancer, inflammatory breast cancer, glioblastoma multiforme, medulloblastoma, pituitary cancer, brain stem glioma, astrocytoma, oligodendroglioma, hemangiopericytoma, germ cell tumor, pineal tumor, chordoma, chondrosarcoma, osteosarcoma, Ewing's sarcoma, fibrosarcoma, adamantinoma, giant cell tumor, head and neck squamous cell carcinoma (HNSCC), salivary gland cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, thyroid cancer, or parathyroid cancer. Cancer, paranasal sinus and nasal cancer, ovarian cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, kidney cancer, urethral cancer, urothelial cancer, bladder cancer, kidney or ureter cancer, renal pelvis cancer, testicular cancer, penile cancer, adrenal gland cancer, anal cancer, bile duct cancer, colon cancer, small intestine cancer, esophageal cancer, gallbladder cancer, gastrointestinal stromal tumor, liver cancer, pancreatic cancer, rectal cancer, gastric cancer, uveal melanoma, retinoblastoma, Merkel cell carcinoma, intraocular melanoma, mucosa-associated lymphoid tissue lymphoma, orbital lymphoma, orbital sarcoma, lacrimal gland tumor, non-small cell Lung cancer, small cell lung cancer, mesothelioma, thymic malignancies, tracheal tumors, some esophageal cancers, chronic or acute leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) (including non-T-cell ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), Waldenström's macroglobulinemia, primary mediastinal large B-cell lymphoma (PMBC), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), transformed 29. The pharmaceutical agent of any one of claims 16 to 28, wherein the patient is suffering from a cancer selected from the group consisting of follicular lymphoma, splenic marginal zone lymphoma (SMZL), cutaneous T-cell lymphoma (CTCL), lymphocytic lymphoma, primary CNS lymphoma, multiple myeloma, CNS; atypical teratoid / rhabdoid tumor, spinal axis tumor, tumor angiogenesis, Kaposi's sarcoma, epidermoid carcinoma, environmentally induced cancers including asbestos induced cancers, other B-cell malignancies, neuroblastoma, olfactory neuroblastoma, rhabdomyosarcoma, and any combination thereof.
30. The pharmaceutical agent described in any one of claims 16 to 29, wherein the tumor is a metastatic tumor.
31. A pharmaceutical described in any one of claims 16 to 30, which induces tumor shrinkage in a subject.
32. The pharmaceutical agent according to any one of claims 1 to 31, wherein the checkpoint inhibitor is a PD-L1 inhibitor, a PD-1 inhibitor, or a CTLA-4 inhibitor.
33. The pharmaceutical of any one of claims 1 to 32, wherein the checkpoint inhibitor is an antibody.
34. The pharmaceutical agent of any one of claims 1 to 33, wherein the checkpoint inhibitor comprises pembrolizumab, nivolumab, cemiplimab, toripalimab, spartalizumab, dostallimab-gxly, tislelizumab, balstilimab, BI-754091, dimvelelimab, INCMGA00012, camrelizumab, or any combination thereof.
35. The pharmaceutical described in claim 34, wherein the checkpoint inhibitor is pembrolizumab or nivolumab.
36. Use of a pharmaceutical agent described in any one of claims 1 to 15 for the manufacture of a medicament for use in combination therapy or prevention, wherein the first composition and the second composition are formulated for separate administration.
37. 37. The use according to claim 36, wherein the treatment or prevention comprises a use according to any one of claims 16 to 35.
38. The pharmaceutical of any one of claims 1 to 35, wherein the first nucleic acid comprises SEQ ID NO:77 and the second nucleic acid comprises SEQ ID NO:
8.
39. The use described in claim 36, wherein the first nucleic acid comprises SEQ ID NO:77 and the second nucleic acid comprises SEQ ID NO:
8.
40. The pharmaceutical described in claim 38, wherein the first IL-12 subunit comprises SEQ ID NO:80 and the second IL-12 subunit comprises SEQ ID NO:
81.
41. The use described in claim 39, wherein the first IL-12 subunit comprises SEQ ID NO:80 and the second IL-12 subunit comprises SEQ ID NO:
81.
42. A polynucleotide comprising SEQ ID NO:77 or SEQ ID NO:8 or a combination thereof.
